Agenda

Day 1
07 Jun 2017
Day 2
08 Jun 2017

Poster Set-Up

Posters should be on display from Thursday morning through Friday evening, but it is recommended that all posters remain on display through Sunday so they are available for viewing both at the designated time with the authors (see below) and informally (without authors) at coffee breaks and lunch.

Session 1: Mechanisms of HHT

Invited Speaker: Dr. Anne Eichmann (8:30am – 9:15am) – Oral Presentations  (9:15am – 10:00am)
Anne Eichmann, Ph.D.

Session 2: Treatment of HHT

Invited Speaker (10:20am – 11:05am) – Oral Presentations (11:05am – 12:20pm)
Charles Theuer, M.D., Ph.D.

Session 3: Diagnosis of HHT

Invited Speaker (1:45pm – 2:30pm) – Oral Presentations  (2:30pm – 3:45pm)
Rosemary Akhurst, Ph.D.
Day 3
09 Jun 2017

Session 5: Treatment of HHT

Invited Speaker (8:00am – 8:45am) – Oral Presentations  (8:45am – 9:45am)
Luca Jovine, Ph.D.

Session 6: Diagnosis of HHT

Oral Presentations  (10:05am – 12:05pm)
Day 4
10 Jun 2017

Session 8: Treatment of HHT

Invited Speaker (8:00am – 8:45am) – Oral Presentations  (8:45am – 9:45am)
Aravind Asokan, Ph.D.

Session 9: Diagnosis of HHT

Oral Presentations  (10:05am – 12:05pm)

Session 11: Diagnosis of HHT  

Oral Presentations  (3:35pm – 4:35pm)

Session 10: Mechanisms of HHT

Invited Speaker (1:30pm – 2:15pm) Therapeutic potential of ALK1 activating drugs in HHT models Hereditary hemorrhagic telangiectasia (HHT) is a vascular disorder arising from aberrant endothelial cell-driven hypervascularization, and caused by loss-of-function mutations in the BMP9-ALK1-Smad1/5/8 signaling pathway. Interventions that would activate ALK1 signaling might therefore have therapeutic potential in HHT. By screening the NIH clinical collections of FDA-approved drugs, we have recently identified several molecules capable of activating ALK1 signaling in BMP9-challenged C2C12 reporter cells. In human primary endothelial cells (HUVECs), the most potent drug identified, tacrolimus (FK506), activated Smad1/5/8 and opposed the pro-angiogenic transcriptional response of ALK1 loss-of-function...
Read More
Philippe Marambaud, Ph.D.

Honorary Lecture: A Perspective on HHT: AVMs and Interventional Radiology

Honorary Speaker: Dr. Karel terBrugge
Karel terBrugge, M.D., FRCPC
Day 5
11 Jun 2017

Session 12: Mechanism of HHT    

Invited Speaker (8:00am – 8:45am) – Oral Presentations  (8:45am – 9:45am)
Arndt Siekmann, Ph.D.

Session 13: Treatment of HHT  

Oral Presentations  (10:05am – 11:05am)
Download PDF Agenda